Use of proton magnetic resonance spectroscopy in the treatment of psychiatric disorders: A critical update

Dialogues in Clinical Neuroscience

Volumn 15, Issue 3, 2013, Pages 329-337

  Bustillo, Juan R ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

Glutamate; Glutamine; Naa; Schizophrenia; Spectroscopy

Indexed keywords

4 AMINOBUTYRIC ACID; CHOLINE; CLOZAPINE; CREATINE; DAVUNETIDE; GLUTAMIC ACID; GLUTAMINE; HALOPERIDOL; INOSITOL; LITHIUM; N ACETYLASPARTIC ACID; NEFAZODONE; OLANZAPINE; QUETIAPINE; VALPROATE SEMISODIUM; VALPROIC ACID;

ANTERIOR CINGULATE; ARTICLE; BASAL GANGLION; BIPOLAR DISORDER; BIPOLAR MANIA; DRUG MEGADOSE; FRONTAL CORTEX; HUMAN; MAJOR DEPRESSION; MANIA; NEGATIVE SYNDROME; PREFRONTAL CORTEX; PROTON NUCLEAR MAGNETIC RESONANCE; SCHIZOPHRENIA; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT RESPONSE;

GLUTAMATE; GLUTAMINE; NAA; SCHIZOPHRENIA; SPECTROSCOPY;

ANIMALS; BRAIN; GLUTAMIC ACID; GLUTAMINE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MENTAL DISORDERS; PROTONS; TREATMENT OUTCOME;

EID: 84888035253     PISSN: 12948322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Steen RG, Hamer RM, Lieberman JA. Measurement of brain metabolites by 1H magnetic resonance spectroscopy in patients with schizophrenia: a systematic review and meta-analysis. Neuropsychopharmacology. 2005; 30:1949-1962.
2. Kraguljac NV, Reid M, White D, et al. Neurometabolites in schizophrenia and bipolar disorder-a systematic review and meta-analysis. Psychiatry Res. 2012; 203:111-125.
3. Marsman A, van den Heuvel MP, Klomp DW, Kahn RS, Luijten PR, Hulshoff Pol HE. Glutamate in schizophrenia: a focused review and metaanalysis of H-MRS studies. Schizophr Bull. 2013; 39:120-129.
4. Goto N, Yoshimura R, Moriya J, et al. Reduction of brain gammaaminobutyric acid (GABA) concentrations in early-stage schizophrenia patients: 3T Proton MRS study. Schizophr Res. 2009; 112:192-193.
5. Yoon JH, Maddock RJ, Rokem A, et al. GABA concentration is reduced in visual cortex in schizophrenia and correlates with orientation-specific surround suppression. J Neurosci. 2010; 30:3777-3781.
6. Ongur D, Prescot AP, Mccarthy J, Cohen BM, Renshaw PF. Elevated gamma-aminobutyric acid levels in chronic schizophrenia. Biol Psychiatry. 2010; 68:667-670.
7. Kegeles LS, Mao X, Stanford AD, et al. Elevated prefrontal cortex gamma-aminobutyric acid and glutamate-glutamine levels in schizophrenia measured in vivo with proton magnetic resonance spectroscopy. Arch Gen Psychiatry. 2012; 69:449-459.
8. Rowland LM, Kontson K, West J, et al. In Vivo measurements of glutamate, GABA, and NAAG in schizophrenia. Schizophr Bull. In press.
9. Do KQ, Trabesinger AH, Kirsten-Kruger M, et al. Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. Eur J Neurosci. 2000; 12:3721-3728.
10. Theberge J, Williamson KE, Aoyama N, et al. Longitudinal grey-matter and glutamatergic losses in first-episode schizophrenia. Br J Psychiatry. 2007; 191:325-334.
11. Bertolino A, Callicott JH, Mattay VS, et al. The effect of treatment with antipsychotic drugs on brain N-acetylaspartate measures in patients with schizophrenia. Biol Psychiatry. 2001; 49:39-46.
12. Fannon D, Simmons A, Tennakoon L, et al. Selective deficit of hippocampal N-acetylaspartate in antipsychotic-naive patients with schizophrenia. Biol Psychiatry. 2003; 54:587-598.
13. Choe BY, Suh TS, Shinn KS, Lee CW, Lee C, Paik IH. Observation of metabolic changes in chronic schizophrenia after neuroleptic treatment by in vivo hydrogen magnetic resonance spectroscopy. Invest Radiol. 1996; 31:345-352.
14. Bustillo JR, Rowland LM, Jung R, et al. Proton magnetic resonance spectroscopy during initial treatment with antipsychotic medication in schizophrenia. Neuropsychopharmacology. 2008; 33:2456-2466.
15. Szulc A, Galinska B, Tarasow E, et al. Proton magnetic resonance spectroscopy study of brain metabolite changes after antipsychotic treatment. Pharmacopsychiatry. 2011; 44:148-157.
16. Lindquist DM, Hawk RM, Karson CN, Komoroski RA. Effects of antipsychotic drugs on metabolite ratios in rat brain in vivo. Magn Reson Med. 2000; 43:355-358.
17. Bustillo J, Wolff C, Myers-y-Gutierrez A, et al. Treatment of rats with antipsychotic drugs: lack of an effect on brain N-acetyl aspartate levels. Schizophr Res. 2004; 66:31-39.
18. Bustillo J, Barrow R, Paz R, et al. Long-term treatment of rats with haloperidol: lack of an effect on brain N-acetyl aspartate levels. Neuropsychopharmacology. 2006; 31:751-756.
19. Harte MK, Bachus SB, Reynolds GP. Increased N-acetylaspartate in rat striatum following long-term administration of haloperidol. Schizophr Res. 2005; 75:303-308.
20. Chakos MH, Lieberman JA, Bilder RM, et al. Increase in caudate nuclei volumes of first-episode schizophrenic patients taking antipsychotic drugs. Am J Psychiatry. 1994; 151:1430-1436.
21. Ho BC, Andreasen NC, Ziebell S, Pierson R, Magnotta V. Long-term antipsychotic treatment and brain volumes: a longitudinal study of firstepisode schizophrenia. Arch Gen Psychiatry. 2011; 68:128-137.
22. De La Fuente-Sandoval C, Léon-Ortiz P, Azcárraga M, et al. Glutamate levels in the associative striatum before and after 4 weeks of antipsychotic treatment in first-episode psychosis: a longitudinal proton magnetic resonance spectroscopy study. JAMA Psychiatry. In press.
23. Goto N, Yoshimura R, Kakeda S, et al. Six-month treatment with atypical antipsychotic drugs decreased frontal-lobe levels of glutamate plus glutamine in early-stage first-episode schizophrenia. Neuropsychiatr Dis Treat. 2012; 8:119-122.
24. Jarskog LF, Dong Z, Kangarlu A, et al. Effects of davunetide on N-acetylaspartate and choline in dorsolateral prefrontal cortex in patients with schizophrenia. Neuropsychopharmacology. 2013; 38:1245-52.
25. Kaufman MJ, Prescot AP, Ongur D, et al. Oral glycine administration increases brain glycine/creatine ratios in men: a proton magnetic resonance spectroscopy study. Psychiatry Res. 2009; 173:143-149.
26. Das Neves Duarte JM, Kulak A, Gholam-Razaee MM, Cuenod M, Gruetter R, Do KQ. N-acetylcysteine normalizes neurochemical changes in the glutathione-deficient schizophrenia mouse model during development. Biol Psychiatry. 2012; 71:1006-1014.
27. Berk M, Copolov D, Dean O, et al. N-acetyl cysteine as a glutathione precursor for schizophrenia--a double-blind, randomized, placebo-controlled trial. Biol Psychiatry. 2008; 64:361-368.
28. Gigante AD, Bond DJ, Lafer B, Lam RW, Young LT, Yatham LN. Brain glutamate levels measured by magnetic resonance spectroscopy in patients with bipolar disorder: a meta-analysis. Bipolar Disord. 2012; 14:478-487.
29. Yuksel C, Ongur D. Magnetic resonance spectroscopy studies of glutamate- related abnormalities in mood disorders. Biol Psychiatry. 2010; 68:785-794.
30. Bhagwagar Z, Wylezinska M, Jezzard P, et al. Low GABA concentrations in occipital cortex and anterior cingulate cortex in medication-free, recovered depressed patients. Int J Neuropsychopharmacol. 2008; 11:255-260.
31. Hajek T, Bauer M, Pfennig A, et al. Large positive effect of lithium on prefrontal cortex N-acetylaspartate in patients with bipolar disorder: 2-centre study. J Psychiatry Neurosci. 2012; 37:185-192.
32. Silverstone PH, Wu RH, O'Donnell T, Ulrich M, Asghar SJ, Hanstock CC. Chronic treatment with lithium, but not sodium valproate, increases cortical N-acetyl-aspartate concentrations in euthymic bipolar patients. Int Clin Psychopharmacol. 2003; 18:73-79.
33. Friedman SD, Dager SR, Parow A, et al. Lithium and valproic acid treatment effects on brain chemistry in bipolar disorder. Biol Psychiatry. 2004; 56:340-348.
34. Brambilla P, Stanley JA, Sassi RB, et al. 1H MRS study of dorsolateral prefrontal cortex in healthy individuals before and after lithium administration. Neuropsychopharmacology. 2004; 29:1918-1924.
35. O'Donnell T, Rotzinger S, Ulrich M, Hanstock CC, Nakashima TT, Silverstone PH. Effects of chronic lithium and sodium valproate on concentrations of brain amino acids. Eur Neuropsychopharmacol. 2003; 13:220-227.
36. Moore GJ, Bebchuk JM, Parrish JK, et al. Temporal dissociation between lithium-induced changes in frontal lobe myo-inositol and clinical response in manic-depressive illness. Am J Psychiatry. 1999; 156:1902-1908.
37. Lee JH, Adler C, Norris M, et al. 4-T 7Li 3D MR spectroscopy imaging in the brains of bipolar disorder subjects. Magn Reson Med. 2012; 68:363-368.
38. Strawn JR, Patel NC, Chu WJ, et al. Glutamatergic effects of divalproex in adolescents with mania: a proton magnetic resonance spectroscopy study. J Am Acad Child Adolesc Psychiatry. 2012; 51:642-651.
39. Yildiz-Yesiloglu A, Ankerst DP. Review of 1H magnetic resonance spectroscopy findings in major depressive disorder: a meta-analysis. Psychiatry Res. 2006; 147:1-25.
40. Luykx JJ, Laban KG, van den Heuvel MP, et al. Region and state specific glutamate downregulation in major depressive disorder: a meta-analysis of H-MRS findings. Neurosci Biobehav Rev. 2012; 36:198-205.
41. Sanacora G, Mason GF, Rothman DL, Krystal JH. Increased occipital cortex GABA concentrations in depressed patients after therapy with selective serotonin reuptake inhibitors. Am J Psychiatry. 2002; 159:663-665.
42. Sanacora G, Mason GF, Rothman DL, et al. Increased cortical GABA concentrations in depressed patients receiving ECT. Am J Psychiatry. 2003; 160:577-579.
43. Charles HC, Lazeyras F, Krishnan KR, Boyko OB, Payne M, Moore D. Brain choline in depression: in vivo detection of potential pharmacodynamic effects of antidepressant therapy using hydrogen localized spectroscopy. Prog Neuropsychopharmacol Biol Psychiatry. 1994; 18:1121-1127.
44. Sonawalla SB, Renshaw PF, Moore CM, et al. Compounds containing cytosolic choline in the basal ganglia: a potential biological marker of true drug response to fluoxetine. Am J Psychiatry. 1999; 156:1638-1640.
45. Luborzewski A, Schubert F, Seifert F, et al. Metabolic alterations in the dorsolateral prefrontal cortex after treatment with high-frequency repetitive transcranial magnetic stimulation in patients with unipolar major depression. J Psychiatr Res. 2007; 41:606-615.
46. Michael N, Erfurth A, Ohrmann P, Arolt V, Heindel W, Pfleiderer B. Metabolic changes within the left dorsolateral prefrontal cortex occurring with electroconvulsive therapy in patients with treatment resistant unipolar depression. Psychol Med. 2003; 33:1277-1284.
47. Sanacora G, Fenton LR, Fasula MK, et al. Cortical gamma-aminobutyric acid concentrations in depressed patients receiving cognitive behavioral therapy. Biol Psychiatry. 2006; 59:284-286.
48. Michael N, Erfurth A, Ohrmann P, Arolt V, Heindel W, Pfleiderer B. Neurotrophic effects of electroconvulsive therapy: a proton magnetic resonance study of the left amygdalar region in patients with treatment-resistant depression. Neuropsychopharmacology. 2003; 28:720-725.
49. Ende G, Braus DF, Walter S, Weber-Fahr W, Henn FA. The hippocampus in patients treated with electroconvulsive therapy: a proton magnetic resonance spectroscopic imaging study. Arch Gen Psychiatry. 2000; 57:937-943.
50. Gonul AS, Kitis O, Ozan E, et al. The effect of antidepressant treatment on N-acetyl aspartate levels of medial frontal cortex in drug-free depressed patients. Prog Neuropsychopharmacol Biol Psychiatry. 2006; 30:120-125.
51. Block W, Traber F, von Widdern O, et al. Proton MR spectroscopy of the hippocampus at 3 T in patients with unipolar major depressive disorder: correlates and predictors of treatment response. Int J Neuropsychopharmacol. 2009; 12:415-422.
52. Taylor MJ, Godlewska BR, Norbury R, Selvaraj S, Near J, Cowen PJ. Early increase in marker of neuronal integrity with antidepressant treatment of major depression: 1H-magnetic resonance spectroscopy of N-acetyl-aspartate. Int J Neuropsychopharmacol. 2012; 15:1541-1546.
53. Salvadore G, van der Veen JW, Zhang Y, et al. An investigation of aminoacid neurotransmitters as potential predictors of clinical improvement to ketamine in depression. Int J Neuropsychopharmacol. 2012; 15:1063-1072.